Why this broker is tipping the ResMed share price to rise 17%

A leading broker says ResMed shares can rise strongly from here…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price is having a strong day on Wednesday.

In afternoon trade, the sleep treatment company's shares are up a decent 3% to $32.52.

This latest gain means that the ResMed share price is now up an impressive 13% since this time last month.

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements

Image source: Getty Images

Can the ResMed share price keep rising from here?

The good news for investors is that one leading broker doesn't believe the company's shares have peaked just yet. In fact, its analysts continue to see ResMed as one of the best options for investors in July.

According to a note out Morgans, its analysts have kept the company's shares on their best ideas list with an add rating and $37.95 price target.

Based on the current ResMed share price, this implies potential upside of almost 17% for investors over the next 12 months.

Why is the broker bullish?

Morgans is bullish on ResMed due to its belief that the company is well-placed for long term growth thanks to its patient-centric connected-care digital platform.

And while it acknowledges that the near term could be a touch volatile, it thinks investors should look beyond this and focus more on the long term opportunity.

The broker commented:

While we believe the next few quarters will likely be volatile, as Covid-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

All in all, this could make ResMed shares worth considering if you're on the lookout for options in the healthcare sector right now.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

2 ASX healthcare stocks tipped to return 34% to 63%

These companies could be poised for much bigger things.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
ASX Share Market News

Are Pro Medicus shares now too cheap to ignore?

The discount looks tempting, but slowing growth could expose valuation risks.

Read more »

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »